In today's ICTM seminar, Elizabeth Higgs will take us on a journey through emergency research responses in the past decade. Drawing on examples of emerging diseases, i Elizabeth will discuss how the international community came together to define core elements of emergency research.

We ran a pharmacokinetic sub-study within the CHAPAS-4 trial, which found that darunavir exposures in the trial are within a safe range. The sub-study included African children with #HIV taking once-daily darunavir/ritonavir for 2nd line treatment.

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

AbstractBackground. Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within

Congratulations to our PhD candidate Gideon Asamoah! Gideon was joint winner in the Student Poster Award category at last week's #ICTMC2024 conference. 🎉

And watch this short video for more👇 https://buff.ly/3ZQYd63

25 at 25: Defining treatment for ovarian cancer

In this article in our series celebrating 25 years of smarter studies, global impact and better health, we look at how the MRC CTU at UCL has helped define t...

Over the last 50 years, #OvarianCancer#ClinicalTrialshttps://buff.ly/3zGwbj4

How did two #ClinicalTrials#tuberculosis#TBhttps://buff.ly/3zMjMtR

RNA viruses can cause chronic infections in immunosuppressed children. In today's ICTM seminar, Seilesh Kadambari & Judith Breuer from UCL Institute for Child Health will discuss their experiences at Great Ormond Street Hospital & rationale for future #ClinicalTrials of new or repurposed drugs.